Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL - Seite 3

Fibromyalgia is a complex and challenging disorder that affects millions of individuals worldwide. The anticipated topline results by the end of December 2023, if successful, could support the submission of a New Drug Application (NDA) to the FDA. Tonix's efforts hold the potential to bring relief and improve the quality of life for those struggling with this debilitating disorder.

*Tonix's product development candidates, including TNX-102 SL, are investigational new drugs or biologics and have not been approved for any indication.

Featured photo by National Cancer Institute on Unsplash.

Contact:

Tonix Pharmaceuticals Holding Corp.
Jessica Morris (corporate)
[e-mail]

SOURCE: Tonix Pharmaceuticals

View the original press release on accesswire.com


The Tonix Pharmaceuticals Holding Stock at the time of publication of the news with a fall of -27,52 % to 0,368USD on Tradegate stock exchange (09. Mai 2023, 22:26 Uhr).